Literature DB >> 10782671

4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB.

C J Andres1, J J Bronson, S V D'Andrea, M S Deshpande, P J Falk, K A Grant-Young, W E Harte, H T Ho, P F Misco, J G Robertson, D Stock, Y Sun, A W Walsh.   

Abstract

4-Thiazolidinones were synthesized and evaluated for their ability to inhibit the bacterial enzyme MurB. Selected 4-thiazolidinones displayed activity against the enzyme in vitro. This activity, coupled with the design principles of the thiazolidinones, supports the postulate that 4-thiazolidinones may be recognized as diphosphate mimics by a biological selector.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10782671     DOI： 10.1016/s0960-894x(00)00073-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  25 in total

1.  3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria.

Authors:  Youjun Yang; Anatoly Severin; Rajiv Chopra; Girija Krishnamurthy; Guy Singh; William Hu; David Keeney; Kristine Svenson; Peter J Petersen; Pornpen Labthavikul; David M Shlaes; Beth A Rasmussen; Amedeo A Failli; Jay S Shumsky; Kristina M K Kutterer; Adam Gilbert; Tarek S Mansour
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 2.  Targeting the formation of the cell wall core of M. tuberculosis.

Authors:  Clifton E Barry; Dean C Crick; Michael R McNeil
Journal:  Infect Disord Drug Targets       Date:  2007-06

Review 3.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

Review 4.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Structural and functional features of enzymes of Mycobacterium tuberculosis peptidoglycan biosynthesis as targets for drug development.

Authors:  Gleiciane Leal Moraes; Guelber Cardoso Gomes; Paulo Robson Monteiro de Sousa; Cláudio Nahum Alves; Thavendran Govender; Hendrik G Kruger; Glenn E M Maguire; Gyanu Lamichhane; Jerônimo Lameira
Journal:  Tuberculosis (Edinb)       Date:  2015-01-29       Impact factor: 3.131

6.  Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG).

Authors:  Kristin E Finch; Claire E Knezevic; Amanda C Nottbohm; Kathryn C Partlow; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2012-01-26       Impact factor: 5.100

7.  First small molecular inhibitors of T. brucei dolicholphosphate mannose synthase (DPMS), a validated drug target in African sleeping sickness.

Authors:  Terry K Smith; Benjamin L Young; Helen Denton; David L Hughes; Gerd K Wagner
Journal:  Bioorg Med Chem Lett       Date:  2009-01-30       Impact factor: 2.823

8.  8-Methyl-4-morpholinoethyl-1-thia-4-aza-spiro-[4.5]decan-3-one.

Authors:  Mehmet Akkurt; Serife Pınar Yalçın; Nalan Terzioğlu Klip; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-07-23

9.  Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl-benzylidene)-thiazolidine-2,4-diones.

Authors:  S Chandrappa; S B Benaka Prasad; K Vinaya; C S Ananda Kumar; N R Thimmegowda; K S Rangappa
Journal:  Invest New Drugs       Date:  2008-05-13       Impact factor: 3.850

10.  One-pot synthesis, biological evaluation and molecular docking studies of fused thiazolo[2,3-b]pyrimidinone-pyrazolylcoumarin hybrids.

Authors:  Ramesh Gondru; Saikiran Reddy Peddi; Vijjulatha Manga; Manjulatha Khanapur; Rajitha Gali; Narsimha Sirassu; Rajitha Bavantula
Journal:  Mol Divers       Date:  2018-07-02       Impact factor: 2.943
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.